Safety of Secukinumab from 1  Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials

ConclusionSecukinumab safety profile with increased patient exposure remained favorable. Paradoxical skin reactions were identified in post-marketing monitoring.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research